hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06330038, orgStudyIdInfo id: SMC 2024-01-065, briefTitle: Anesthesia and Non-small Cell Lung Cancer Recurrence, acronym: GASTIVA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Samsung Medical Center, class: OTHER, collaborators name: Seoul National University Hospital, collaborators name: Asan Medical Center, collaborators name: Severance Hospital, collaborators name: Seoul St. Mary's Hospital, collaborators name: Korea University Guro Hospital, collaborators name: DongGuk University, collaborators name: Inha University Hospital, collaborators name: Konkuk University Medical Center, collaborators name: Ewha Womans University, collaborators name: Chungnam National University Hospital, collaborators name: University of Virginia, collaborators name: Memorial Sloan Kettering Cancer Center, collaborators name: Yale University, collaborators name: Mayo Clinic, collaborators name: University of Texas Southwestern Medical Center, collaborators name: University Hospitals Coventry and Warwickshire NHS Trust, collaborators name: Khon Kaen University, collaborators name: King Chulalongkorn Memorial Hospital, collaborators name: The Affiliated Hospital of Qingdao University, collaborators name: Beijing Hospital, collaborators name: All India Institute of Medical Sciences, New Delhi, descriptionModule briefSummary: There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials., conditionsModule conditions: Non-small Cell Lung Cancer, conditions: Surgery, conditions: Anesthesia, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 5384, type: ESTIMATED, armsInterventionsModule interventions name: Propofol, interventions name: Inhaled anesthetics, outcomesModule primaryOutcomes measure: Recurrence free survival, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Postoperative complications, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06330012, orgStudyIdInfo id: GeoMx_Breast, briefTitle: The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2025-01-15, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Samsung Medical Center, class: OTHER, descriptionModule briefSummary: This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients., conditionsModule conditions: HER2-positive Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: GeoMx data analysis with clinical outcome, outcomesModule primaryOutcomes measure: Spatial transcriptomic analysis, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ji-Yeon Kim, status: RECRUITING, city: Seoul, zip: 06351, country: Korea, Republic of, contacts name: Ji-Yeon Kim, role: CONTACT, phone: 82-2-3410-3459, email: jyeon25@skku.edu, contacts name: MIRYOUNG HONG, role: CONTACT, phone: 82-2-2148-7147, email: ring7629@naver.com, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06329999, orgStudyIdInfo id: CMG-sAML-001, briefTitle: A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-03, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Ruijin Hospital, class: OTHER, collaborators name: Huadong Hospital, collaborators name: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, collaborators name: Huashan Hospital, collaborators name: Army Medical Center of PLA, collaborators name: Sun Yat-sen University, collaborators name: RenJi Hospital, collaborators name: Shanghai Jiading District Central Hospital, collaborators name: The Second Affiliated Hospital of Dalian Medical University, collaborators name: First Hospital of China Medical University, collaborators name: Dalian Municipal Central Hospital, collaborators name: Shanghai Zhongshan Hospital, collaborators name: Shanghai Pudong Hospital, collaborators name: Shanghai Public Health Clinical Center, collaborators name: Xuhui Central Hospital, Shanghai, collaborators name: The Affiliated People's Hospital of Ningbo University, collaborators name: Taizhou First People's Hospital, collaborators name: Wenzhou People's Hospital, descriptionModule briefSummary: The goal of this clinical trial\] is to evaluate mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven) in adult secondary acute myeloid leukemia and myelodysplastic syndrome with increased primordial cells type 2(MDS-IB2) or elderly acute myeloid leukemia\]. The main questions it aims to answer are:* Evaluation of the efficacy* Evaluation of the safety, conditionsModule conditions: Recurrent Adult Acute Myeloid Leukemia, conditions: Myelodysplastic Syndrome, conditions: Adult Acute Myeloid Leukemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 78, type: ESTIMATED, armsInterventionsModule interventions name: CMGV, outcomesModule primaryOutcomes measure: CRc, secondaryOutcomes measure: ORR, secondaryOutcomes measure: OS, secondaryOutcomes measure: RFS, secondaryOutcomes measure: MRD-, secondaryOutcomes measure: Adverse Event, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ruijin Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, country: China, contacts name: xiaoqian Xu, Doctor, role: CONTACT, phone: 13816205940, email: Ellenxxq@qq.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06329986, orgStudyIdInfo id: SEDPTC20240109, briefTitle: Crossover RCT of TAMER Lenses in Myopia Control, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-24, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Shanghai Eye Disease Prevention and Treatment Center, class: OTHER, descriptionModule briefSummary: This study is a prospective, randomized, crossover clinical trial with a planned proposed enrollment of 120 Chinese male and female subjects aged 6-12 years without systemic or ocular diseases to follow up their cycloplegic equivalent spherical lens power and other relevant indices in order to determine the role of TAMER lenses in myopia control as compared to singlie vision lenses., conditionsModule conditions: Myopia, conditions: Progressive, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: TAMER Lens Spectacle, interventions name: SV lenses, outcomesModule primaryOutcomes measure: Spherical Equivalent change, secondaryOutcomes measure: Axial Length change, secondaryOutcomes measure: Spherical Equivalent change, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Shanghai Eye Disease Prevention and Treatment Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200041, country: China, contacts name: Xiangui He, role: CONTACT, phone: 021-62982727-817, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06329973, orgStudyIdInfo id: 2023-237, briefTitle: Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2025-12-15, completionDateStruct date: 2028-02-15, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Henan Cancer Hospital, class: OTHER_GOV, descriptionModule briefSummary: Based on the current status and progress in the treatment of gastric cancer, our center prospectively designed a first-line comprehensive treatment plan for unresectable or postoperative recurrent advanced gastric/gastroesophageal conjoint adenocarcinoma, fruquintinib + sintilimab + oxaliplatin + Capecitabine (CAPEOX), which utilizes the tumor immunomodulation and vascular normalization effects of fruquintinib. While improving the effective perfusion of intravenous chemotherapy with CAPEOX regimen, further combining with PD-1 monoclonal antibody to regulate the immunosuppressive microenvironment and reactivate the anti-tumor immune response of the body. An exploratory dose-climbing trial was designed to evaluate the clinical efficacy and safety of fruquintinib in combination with Sintilimab and CAPEOX in clinical practice. At the same time, changes in genome, pathology and immune microenvironment of tumor-related tissues before and after treatment were observed, and molecular markers related to curative effect were screened to explore the molecular mechanism affecting the curative effect of combination therapy, and further enrichment of therapeutic advantage groups to improve the surgical conversion rate laid the foundation for future large-scale clinical studies, conditionsModule conditions: Metastatic Gastroesophageal Junction Adenocarcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Fruquintinib in combination with Sintilimab and CAPEOX, outcomesModule primaryOutcomes measure: Objective response rate, primaryOutcomes measure: Maximum tolerated dose, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Progression Free Survival, secondaryOutcomes measure: Disease Control Rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Henan Cancer Hospital, status: RECRUITING, city: Zhengzhou, state: Henan, zip: 450008, country: China, contacts name: Xiaobing Chen, role: CONTACT, phone: +8613937100233, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06329960, orgStudyIdInfo id: 2024PHB019-001(3), briefTitle: Dorsal Scapular Nerve Injection Combined With Muscle Needle Release, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Peking University People's Hospital, class: OTHER, descriptionModule briefSummary: Ultrasound-guided perineural injection (PIT) of 5% dextrose (D5W) hydrodissection has been widely used in the treatment of peripheral entrapment neuropathies. However, there are few studies investigating the efficacy of PIT using D5W HD for dorsal scapular nerve (DSN) entrapment. Generally, the DSN entrapment causes the stiffness of the major and minor rhomboideus(2). In clinical practice, the investigators observed that ultrasound-guided PIT using D5W HD combined with needle release of major and minor rhomboideus significantly relieved the pain of scapular region. Therefore, the investigators aimed to evaluate the 6-month efficacy of this procedure for the participants with DSN entrapment., conditionsModule conditions: Dorsal Scapular Nerve Entrapment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound-guided injection combined with needle release, outcomesModule primaryOutcomes measure: visual analogue scale (VAS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jiaan Zhu, city: Beijing, country: China, contacts name: Jiaan Zhu, role: CONTACT, email: canzhujia@126.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06329947, orgStudyIdInfo id: HMPL-012-SPRING-P106, briefTitle: A Phase II Study of Surufatinib Combined With PD-L1 and mFOLFOX6 as Second-line Treatment for Advanced PRAD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-22, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2026-09-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Rui-hua Xu, MD, PhD, class: OTHER, descriptionModule briefSummary: To preliminarily evaluate whether there is a survival benefit of surufatinib in combination with Caralizumab and mFOLFOX6 in the second-line treatment of advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer, conditionsModule conditions: Advanced Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 37, type: ESTIMATED, armsInterventionsModule interventions name: Surufatinib in combination with Caralizumab and mFOLFOX6, outcomesModule primaryOutcomes measure: objective response rate (ORR), secondaryOutcomes measure: disease control rate (DCR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: overall survival (OS), secondaryOutcomes measure: quality of life (QoL), secondaryOutcomes measure: adverse events (AE), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: SunYat-senUniversity Cancer Center, city: Guangzhou, country: China, geoPoint lat: 23.11667, lon: 113.25, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2023-12-12, uploadDate: 2024-03-18T20:39, filename: Prot_000.pdf, size: 1380851, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2023-12-12, uploadDate: 2024-03-18T20:39, filename: ICF_001.pdf, size: 541718, hasResults: False
protocolSection identificationModule nctId: NCT06329934, orgStudyIdInfo id: XXZY-003, briefTitle: Refined Nursing in Rehabilitation Training, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-01, primaryCompletionDateStruct date: 2023-05-31, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Xinxiang Central Hospital, class: OTHER, descriptionModule briefSummary: This study is to explore the clinical effect of refined nursing in rehabilitation training for patients with brain injury during the recovery period. Patients in the control group were provided with routine nursing intervention, while patients in the study group adopted a nursing mode based on the concept of refinement treatment. Comparison was made in terms of the Glasgow Coma Scale (GCS) score, cognitive function score, functional independence score, nursing satisfaction, and incidence of complications., conditionsModule conditions: Brain Injuries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 96, type: ACTUAL, armsInterventionsModule interventions name: Establishment of a hierarchical monitoring and management team, interventions name: Assessment of pressure injury, interventions name: Communication, interventions name: Intervention for pressure ulcer, interventions name: Rehabilitation training, interventions name: introduction of the current patient's condition to family members, interventions name: maintaining appropriate temperature and humidity in the ward, interventions name: careful observation of vital signs in patients, outcomesModule primaryOutcomes measure: GCS scores, primaryOutcomes measure: GCS scores, primaryOutcomes measure: cognitive function scores, primaryOutcomes measure: cognitive function scores, primaryOutcomes measure: functional independence scores, primaryOutcomes measure: functional independence scores, primaryOutcomes measure: Newcastle Satisfaction with Nursing Scale (NSNS), primaryOutcomes measure: Newcastle Satisfaction with Nursing Scale (NSNS), primaryOutcomes measure: incidence of adverse reactions, primaryOutcomes measure: incidence of adverse reactions, eligibilityModule sex: ALL, minimumAge: 33 Years, maximumAge: 43 Years, stdAges: ADULT, contactsLocationsModule locations facility: Effect of Refined Nursing in Rehabilitation Training for Patients with Brain Injury During the Recovery Period: An Observational Study, city: Xinxiang, state: Henan, zip: 453000, country: China, geoPoint lat: 35.19033, lon: 113.80151, hasResults: False
protocolSection identificationModule nctId: NCT06329921, orgStudyIdInfo id: 232192, briefTitle: Inpatient Monitoring of Unfractionated Heparin, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Vanderbilt University Medical Center, class: OTHER, descriptionModule briefSummary: Unfractionated heparin (UFH) is the most widely used intravenous (IV) anticoagulant for treating and preventing thromboembolic disease (e.g., blood clots ). UFH must be closely monitored and adjusted in the hospital. There are two assays used to monitor UFH: 1) the activated partial thromboplastin time (PTT) and 2) the chromogenic anti-factor Xa assay (anti-Xa). This study aims to compare PTT and anti-Xa methods for monitoring UFH in a pragmatic, randomized controlled trial to determine which helps patients reach a therapeutic anticoagulation range faster., conditionsModule conditions: Blood Clot, conditions: Thrombosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study will be performed as a pragmatic, randomized controlled clinical trial with parallel group assignment., primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule interventions name: PTT protocol, interventions name: anti-Xa protocol, outcomesModule primaryOutcomes measure: Time to therapeutic anticoagulation range, secondaryOutcomes measure: Measurements in therapeutic anticoagulation range, secondaryOutcomes measure: Coagulation laboratory measurements, secondaryOutcomes measure: New thrombotic events, secondaryOutcomes measure: New clinically relevant bleeding events, secondaryOutcomes measure: New coagulation events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vanderbilt University Medical Center, city: Nashville, state: Tennessee, zip: 37232, country: United States, contacts name: Benjamin Tillman, MD, role: CONTACT, geoPoint lat: 36.16589, lon: -86.78444, hasResults: False
protocolSection identificationModule nctId: NCT06329908, orgStudyIdInfo id: TSLG-001, briefTitle: DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-27, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2026-10-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Zhen-Yu Ding, class: OTHER, descriptionModule briefSummary: This is a single-center, single-arm, prospective clinical trial to investigate the safety and efficacy of Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs., conditionsModule conditions: Lung Cancer, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: single arm, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: LG002, outcomesModule primaryOutcomes measure: The safety of Neo-DCVac combined with ICIs., secondaryOutcomes measure: The efficacy of Neo-DCVac combined with ICIs., secondaryOutcomes measure: The efficacy of Neo-DCVac combined with ICIs., otherOutcomes measure: Synergistic anti-tumor mechanism., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: West China Hospital, status: RECRUITING, city: Chengdu, state: Si Chuan, zip: 610000, country: China, contacts name: Zhengyu Ding, MD, role: CONTACT, phone: 18980601957, email: dingzhenyu@scu.edu.cn, contacts name: Qing Li, MD, role: CONTACT, phone: 18702848178, email: liqing@scu.edu.cn, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False